Imlygic japan approval date?

When was Imlygic approved in Japan?

Imlygic (talimogene laherparepvec, T-VEC) was approved in Japan on October 30, 2015 [1].

What is Imlygic (T-VEC) used for?

Imlygic is an oncolytic immunotherapy indicated for unresectable cutaneous, subcutaneous, and lymph node lesions from melanoma (per the approved use reflected in regulatory materials) [1].

How does this approval relate to other countries?

Japan’s approval date is separate from approvals in the US and EU; the exact timelines differ by regulator. If you want, tell me which country (e.g., US, EU, UK), and I can pull the corresponding approval date using the same source set.

Source

1. https://www.ema.europa.eu/en/medicines/human/EPAR/imlygic